|
|
 |
|
 |
| Bioclon Institute, a company of the Silanes Group, is a worldwide leader in the research and development of third generation antivenins. |
| Bioclon Silanes has the approval of the FDA for the use of scorpion, snake, and spider antivenoms in clinical studies in the United States. |
| |
| Mexico City, Mexico. February 9, 2006 |
| The Bioclon Institute, a company of the Silanes Group, received the 2005 National Technology Award in the category of Applied Research Centers, Research Institutons, and Research Entities, from Mexico President Vicente Fox Quezada, in the official residence Los Pinos. |
| |
| |
| Bioclon Silanes is a leader in the area of research and development of third generation antivenoms, named Fabotherapics, which are characterized by a high degree of safety and broad efficacy, and have succeeded in reducing complications and mortality in patients injured by poisonous animals. |
| |
| According to Bioclon Institute President Lic. Juan López de Silanes , "the competitive advantages have been a result of efforts developed under a strategic plan based on continual innovation of processes and products, using a model of technology management supported by a strong academic-industrial connections program that seeks to promote modernization and impel research on a national level through grants and stimuli for researchers, development of providers, and improvement in manufacturing processes. |
| |
| |
 |
| |
| It is worth mentioning that the Bioclon Institute and Silanes Laboratories, which comprise part of the Silanes Group, together invested 8% of their sales in research and development of innovative health care products, which has enabled them to achieve an important position in this field, both nationally and internationally. |
| |
| Currently, Bioclon Silanes markets its products in Mexico and several countries in Central and South America; and has begun to enter markets in the United States, Australia, Europe, Africa, and the Middle East. It is important to remember that this is the only Mexican company that has received approval by the Food and Drug Administration (FDA) for conducting clinical studies in the Unites States with fabotherapics. The approved products are: Aracmyn®, for spider bites, Alacramyn®, for scorpion stings, and Antivipmyn®, for bites by snakes belonging to the Viperidae family. |
| |
| In Mexico, four antivenoms are included in the basic group of health sector drugs and, as a result, to which any institution has access: Anti-scorpion fabotherapic, Anti-arachnid fabotherapic, Anti-viper fabotherapic, Anti-coral fabotherapic. |
| |
| The quality of their products is a permanent commitment by the company. For example, the Certificación Internacional de Buenas Prácticas de Manufactura (International Certification for Good Manufacturing Practices) was granted to Bioclon by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) (National Institute for Drug and Food Monitoring), of Columbia's Minister of Social Protection, and by COFEPRIS, Mexico. |
| |
 |
| |
| The Bioclon Institute and Silanes updates more than 20 thousand physicians, nurses, and technicians in the health field about diagnosing and treating injuries caused by poisonous animals, in addition to supporting the Red Internacional de Toxinología "Redtox" (International Toxinology Network), which provides consulting and information on the topic via their internet website www.redtox.org. |
| |
| "With the use of fabotherapics, Mexico's health institutes, and those in other areas of the world, have achieved the reducing not only the complexity and mortality of cases, but also lowering the treatment costs for persons infected with animal poisons," emphasized Lic. Juan López de Silanes. |
| |
|
 |
| |
© Instituto Bioclon S.A. de C.V. 2006. |
Calzada de Tlalpan # 4687, Col. Toriello Guerra. C.P. 14050, México D.F., Tel 56-65-41-11 |
 |
|
